Last reviewed · How we verify
Dornase alpha
At a glance
| Generic name | Dornase alpha |
|---|---|
| Also known as | rhDNase, pulmozyme |
| Sponsor | Syntara |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection
- Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic (NA)
- Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (PHASE2)
- Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. (PHASE1)
- VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema (NA)
- Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer. (PHASE2)
- Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |